Clinical outcome and social participation according to prophylactic regimen
| . | Netherlands, intermediate-dose median (IQR) . | Sweden, high-dose median (IQR) . | P . |
|---|---|---|---|
| Physical activity METs | 4294 (1037-13 740) | 3200 (1152-9292) | .50 |
| Bleeding | |||
| Joint bleeds per y, n | 1.3 (0.8-2.7) | 0 (0.0-2.0) | <.01 |
| Joint bleeds in 5 y, n | 10 (4-18) | 2.5 (0-9.3) | <.01 |
| Joint outcome | |||
| Loss of function, HJHS, maximum, 144 points | 9.0 (2.0-18.0) | 4.0 (2.0-6.8) | .01 |
| HJHS≥ 10 points | 31/68 (46%) | 5/44 (11%) | <.01 |
| Nr of joints affected | 2 (1-4) | 3 (2-3) | .47 |
| Limitations in activities | 93 (81-98) | 99 (93-100) | <.01 |
| Haemophilia Activities List sum, maximum 100 | |||
| Health-related quality of life | |||
| EQ-5D utility | 0.84 (0.81-1.00) | 1.00 (0.81-1.00) | .93 |
| . | Netherlands, intermediate-dose median (IQR) . | Sweden, high-dose median (IQR) . | P . |
|---|---|---|---|
| Physical activity METs | 4294 (1037-13 740) | 3200 (1152-9292) | .50 |
| Bleeding | |||
| Joint bleeds per y, n | 1.3 (0.8-2.7) | 0 (0.0-2.0) | <.01 |
| Joint bleeds in 5 y, n | 10 (4-18) | 2.5 (0-9.3) | <.01 |
| Joint outcome | |||
| Loss of function, HJHS, maximum, 144 points | 9.0 (2.0-18.0) | 4.0 (2.0-6.8) | .01 |
| HJHS≥ 10 points | 31/68 (46%) | 5/44 (11%) | <.01 |
| Nr of joints affected | 2 (1-4) | 3 (2-3) | .47 |
| Limitations in activities | 93 (81-98) | 99 (93-100) | <.01 |
| Haemophilia Activities List sum, maximum 100 | |||
| Health-related quality of life | |||
| EQ-5D utility | 0.84 (0.81-1.00) | 1.00 (0.81-1.00) | .93 |
EQ-5D, utility values according to the Dutch tariff; Haemophilia Activities List; HJHS, Haemophilia Joint Health Score; IU, international units; METs, metabolic equivalent of task units.